Pharmaxis is a pharmaceutical research company with approved products in the market and a drug discovery team working on a pipeline of new medicines to treat inflammation and fibrosis.
In May 2015 Pharmaxis demonstrated sold a phase 1 drug (BI 1467335 (formerly known as PXS 4728A) to pharmaceutical company Boehringer Ingelheim for A$40 million in up-front payments. In a 12 week Phase 2a trial BI 1467335 showed safety and efficacy in the treatment of the liver disease NASH, however Boehringer elected not to proceed with further development due to the potential for drug interactions. BI 1467335 is currently being developed for diabetic retinopathy, a leading cause of blindness.
Separately, Pharmaxis is working towards approval of its cystic fibrosis drug Bronchitol in the United States and has partnered with Chiesi Farmaceutici SpA to reduce overall investment while retaining a key stake in the future commercial success of Bronchitol in global markets.
In order to manage risk and maximise the number of new drugs developed from the Company’s established amine oxidase chemistry platform Pharmaxis has a LOXL2 research collaboration with UK biotech company Synairgen. In December 2017 the collaboration was amended to facilitate the commercialisation of the program. Read more.
Pharmaxis’ business strategy is to bring drug candidates to phase 1 or phase 2 of clinical development before seeking a commercial partner. The timing of partnerships is determined on a project by project basis. Further details of the Pharmaxis product pipeline are available here.
Read a case study on Pharmaxis prepared by Australia's National Health and Medical Research Centre.